PARIS, FRANCE -- (Marketwire) -- 03/22/12 -- Meiogenix, a genomic biotech company developing a technology that modulates meiotic recombination (SpiX(R)), has announced the constitution of its Scientific Advisory Board. Dr. Alain Nicolas will chair the SAB, and is joined by Prof. Holger Puchta and Prof. Philip Avner.
Dr. Alain Nicolas is a group leader at the Research Center of the Institut Curie, Paris. Dr. Nicolas pioneered research on the initiation of meiotic recombination in eukaryotic cells and is the inventor of the patented Spo11 Meiogenix's technology that stimulates homologous recombination at targeted sites in the genome.
Prof. Holger Puchta holds the chair of plant molecular biology and biochemistry at the Karlsruhe Institute of Technology (KIT) where he elucidated major mechanisms of double-strand break repair in plants. His research interests centre on somatic and meiotic recombination in plants as well as green gene technology.
Prof. Philip Avner is the head of the Developmental Biology Department of the Institut Pasteur where he also heads the Mouse Molecular Genetics Unit. His main research interests are the field of epigenetics and mouse genetics.
"During the past year, Meiogenix has made impressive advances with its R&D programs and I am confident that our scientific advisors will make significant contributions to our current and future R&D programs, thanks to the insights they bring", said Dr. Alain Nicolas, inventor of the SpiX(R) technology.
SpiX(R) can redirect meiotic recombination towards targeted genome areas, and stimulate rare recombination events. This holds promise for the generation of novel, but still natural, genetic diversity, and addresses companies involved in varietal R&D.
Meiogenix is currently evaluating the impact of its technologies in rice and mouse and developing complementary breakthrough technologies to modulate the meiotic recombination. Meiogenix seeks industrial collaborations to apply SpiX(R) in other organisms of commercial relevance.
MEIOGENIX is a French biotech company that holds an exclusive and worldwide license for a technology that modulates the frequency of homologous recombination in eukaryotic cells. This technology facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties with commercial potential. www.meiogenix.com
Contacts: Meiogenix Giacomo Bastianelli Chief Executive Officer + 33 (0) 6 69 26 28 09 firstname.lastname@example.org www.meiogenix.com